The DOI matches its Crossref record; 112 of the 112 references it cites were found in a registry or an index.
Quinoline as a Privileged Scaffold in Cancer Drug Discovery
Abstract
Quinoline (1-azanaphthalene) is a heterocyclic aromatic nitrogen compound characterized by a double-ring structure that contains a benzene ring fused to pyridine at two adjacent carbon atoms. Quinoline compounds are widely used as "parental" compounds to synthesize molecules with medical benefits, especially with anti-malarial and anti-microbial activities. Certain quinoline-based compounds also show effective anticancer activity. This broad spectrum of biological and biochemical activities has been further facilitated by the synthetic versatility of quinoline, which allows the generation of a large number of structurally diverse derivatives. This includes numerous analogues derived from substitution of the quinoline ring system, and derivatization of quinoline ring structure. Quinoline and its analogs have recently been examined for their modes of function in the inhibition of tyrosine kinases, proteasome, tubulin polymerization and DNA repair. In this review, we have summarized our knowledge on quinoline compounds with respect to their anticancer activities, mechanisms of action, structure-activity relationship (SAR), and selective and specific activity against various cancer drug targets. In particular, we focus our review on in vitro and in vivo anticancer activities of quinoline and its analogs in the context of cancer drug development and refinement.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Untangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974
The fundamental role of epigenetic events in cancer
Jones, P. A., & Baylin, S. B. (2002) · Nature Reviews Genetics · doi:10.1038/nrg816 · Cited by 5,648
Multidrug resistance in cancer: role of ATP–dependent transporters
Gottesman, M. M., Fojo, T., & Bates, S. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc706 · Cited by 5,536
Microtubules as a target for anticancer drugs
Jordan, M. A., & Wilson, L. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1317 · Cited by 4,000
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism
Engelman, J. A., Luo, J., & Cantley, L. C. (2006) · Nature Reviews Genetics · doi:10.1038/nrg1879 · Cited by 3,330 · cited 3×
“The PI3K-PKB pathway is one of the major signaling pathways highly active in cancer, often due to deletions, activating mutations, and/or amplification of its players [11].”
BackgroundA surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants
Juliano, R. L., & Ling, V. (1976) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(76)90160-7 · Cited by 3,296
Mitogen-activated protein kinase pathways
Robinson, M. J., & Cobb, M. H. (1997) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(97)80061-0 · Cited by 2,474
PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors
Heinrich, M. C., Corless, C. L., Duensing, A., McGreevey, L., Chen, C.-J., Joseph, N., Singer, S., Griffith, D. J., Haley, A., Town, A., et al. (2003) · Science · doi:10.1126/science.1079666 · Cited by 2,301
The ubiquitin-proteasome proteolytic pathway
Ciechanover, A. (1994) · Cell · doi:10.1016/0092-8674(94)90396-4 · Cited by 1,791
Signal Transduction through MAP Kinase Cascades
(1998) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60765-4 · Cited by 1,759
Defects in the kidney and enteric nervous system of mice lacking the tyrosine kinase receptor Ret
Schuchardt, A., D'Agati, V., Larsson-Blomberg, L., Costantini, F., & Pachnis, V. (1994) · Nature · doi:10.1038/367380a0 · Cited by 1,614
Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions
Kölch, W. (2000) · Biochemical Journal · doi:10.1042/0264-6021:3510289 · Cited by 1,441
Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis
Cully, M., You, H., Levine, A. J., & Mak, T. W. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1819 · Cited by 1,233
Yarden, Y., Escobedo, J. A., Kuang, W.-J., Yang-Feng, T. L., Daniel, T. O., Tremble, P. M., Chen, E. Y., Ando, M. E., Harkins, R. N., Francke, U., et al. (1986) · Nature · doi:10.1038/323226a0 · Cited by 1,209
Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo
Sebolt-Leopold, J. S., Dudley, D. T., Herrera, R., Becelaere, K. V., Wiland, A., Gowan, R. C., Tecle, H., Barrett, S. D., Bridges, A., Przybranowski, S., et al. (1999) · Nature Medicine · doi:10.1038/10533 · Cited by 970
PLATELET-DERIVED GROWTH FACTOR
Ross, R. (1989) · The Lancet · doi:10.1016/s0140-6736(89)92760-8 · Cited by 940
Auger, K. R., Serunian, L. A., Soltoff, S. P., Libby, P., & Cantley, L. C. (1989) · Cell · doi:10.1016/0092-8674(89)90182-7 · Cited by 908
Ubiquitin, proteasomes, and the regulation of intracellular protein degradation
Hochstrasser, M. (1995) · Current Opinion in Cell Biology · doi:10.1016/0955-0674(95)80031-x · Cited by 874
Quinolines and structurally related heterocycles as antimalarials
Kaur, K., Jain, M., Reddy, R. P., & Jain, R. (2010) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2010.04.011 · Cited by 727
Role of Transforming Growth Factor Beta in Human Cancer
Elliott, R. L., & Blobe, G. C. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.047 · Cited by 709
Rosen, O. M. (1987) · Science · doi:10.1126/science.2442814 · Cited by 674
Antitumor Activity of HKI-272, an Orally Active, Irreversible Inhibitor of the HER-2 Tyrosine Kinase
Rabindran, S. K., Discafani, C. M., Rosfjord, E. C., Baxter, M., Floyd, M. B., Golas, J., Hallett, W. A., Johnson, B. D., Nilakantan, R., Overbeek, E., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2868 · Cited by 639
Kinetic and Catalytic Mechanisms of Protein Kinases
Adams, J. A. (2001) · Chemical Reviews · doi:10.1021/cr000230w · Cited by 627
Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature.
Dark, G. G., Hill, S. A., Prise, V. E., Tozer, G. M., Pettit, G. R., & Chaplin, D. J. (1997) · PubMed · Cited by 622
Isolation of a Novel Receptor cDNA Establishes the Existence of Two PDGF Receptor Genes
Matsui, T., Heidaran, M., Miki, T., Popescu, N., La Rochelle, W., Kraus, M., Pierce, J., & Aaronson, S. (1989) · Science · doi:10.1126/science.2536956 · Cited by 596
DNA Cross-Linking Agents as Antitumor Drugs
Rajski, S. R., & Williams, R. M. (1998) · Chemical Reviews · doi:10.1021/cr9800199 · Cited by 592
The Role of ABC Transporters in Drug Resistance, Metabolism and Toxicity
Glavinas, H., Krajcsi, P., Cserepes, J., & Sarkadi, B. (2004) · Current Drug Delivery · doi:10.2174/1567201043480036 · Cited by 558
Chloroquine and its analogs: A new promise of an old drug for effective and safe cancer therapies
Solomon, V. R., & Lee, H. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.06.063 · Cited by 516
Self-citationYarden, Y., & Schlessinger, J. (1987) · Biochemistry · doi:10.1021/bi00379a034 · Cited by 507
Golas, J. M., Arndt, K. T., Etienne, C., Lucas, J., Nardin, D., Gibbons, J. J., Frost, P., Ye, F., Boschelli, D. H., & Boschelli, F. (2003) · PubMed · Cited by 457
Histone acetyltransferases: function, structure, and catalysis
Marmorstein, R., & Roth, S. Y. (2001) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(00)00173-8 · Cited by 401
P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs
Fromm, M. F. (2000) · Int. Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cpp38069 · Cited by 399
Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin
Knight, S. D., Adams, N. D., Burgess, J. L., Chaudhari, A. M., Darcy, M. G., Donatelli, C. A., Luengo, J. I., Newlander, K. A., Parrish, C. A., Ridgers, L. H., et al. (2010) · ACS Medicinal Chemistry Letters · doi:10.1021/ml900028r · Cited by 373
(2001) · PubMed · Cited by 350
Structural and functional studies on platelet-derived growth factor.
Heldin, C. H. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05523.x · Cited by 337
Adsule, S., Barve, V., Chen, D., Ahmed, F., Dou, Q. P., Padhye, S., & Sarkar, F. H. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060712l · Cited by 334
Daniel, K. G., Chen, D., Orlu, S., Cui, Q. C., Miller, F. R., & Dou, Q. P. (2005) · Breast Cancer Research · doi:10.1186/bcr1322 · Cited by 326
Tsou, H.-R., Overbeek-Klumpers, E. G., Hallett, W. A., Reich, M. F., Floyd, M. B., Johnson, B. D., Michalak, R. S., Nilakantan, R., Discafani, C., Golas, J., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm040159c · Cited by 301
Enomoto, H., Crawford, P. A., Gorodinsky, A., Heuckeroth, R. O., Johnson, E. M., & Milbrandt, J. (2001) · Development · doi:10.1242/dev.128.20.3963 · Cited by 298
Wissner, A., Overbeek, E., Reich, M. F., Floyd, M. B., Johnson, B. D., Mamuya, N., Rosfjord, E. C., Discafani, C., Davis, R., Shi, X., et al. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm020241c · Cited by 264
The molecular interaction of the high affinity reversal agent XR9576 with P‐glycoprotein
Martin, C., Berridge, G., Mistry, P., Higgins, C., Charlton, P., & Callaghan, R. (1999) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0702807 · Cited by 258
Siemann, D. W., Chaplin, D. J., & Walicke, P. A. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780802691068 · Cited by 250
Musiol, R., Serda, M., Hensel-Bielowka, S., & Polanski, J. (2010) · Current Medicinal Chemistry · doi:10.2174/092986710791163966 · Cited by 249
Overexpression and Activation of the Tyrosine Kinase Src in Human Pancreatic Carcinoma
Lutz, M. P., Eßer, I. B. S., Flossmann-Kast, B. B. M., Vogelmann, R., Lührs, H., Friess, H., Büchler, M. W., & Adler, G. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.8043 · Cited by 249
The drug efflux–metabolism alliance: biochemical aspects
Benet, L. Z., & Cummins, C. L. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(01)00178-8 · Cited by 226
Optimization of 4-Phenylamino-3-quinolinecarbonitriles as Potent Inhibitors of Src Kinase Activity
Boschelli, D. H., Ye, F., Wang, Y. D., Dutia, M., Johnson, S. L., Wu, B., Miller, K., Powell, D. W., Yaczko, D., Young, M., et al. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm0102250 · Cited by 217
Wissner, A., Berger, D. M., Boschelli, D. H., Floyd, M. B., Greenberger, L. M., Gruber, B. C., Johnson, B. D., Mamuya, N., Nilakantan, R., Reich, M. F., et al. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm000206a · Cited by 207
Manske, R. H. (1942) · Chemical Reviews · doi:10.1021/cr60095a006 · Cited by 206
Tying It All Together: Epigenetics, Genetics, Cell Cycle, and Cancer
Baylin, S. B. (1997) · Science · doi:10.1126/science.277.5334.1948 · Cited by 202
Structure‐function relationships in Src family and related protein tyrosine kinases
Superti‐Furga, G., & Courtneidge, S. A. (1995) · BioEssays · doi:10.1002/bies.950170408 · Cited by 200
Switching on kinases: oncogenic activation of BRAF and the PDGFR family
Dibb, N. J., Dilworth, S. M., & Mol, C. D. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1434 · Cited by 179
The Development of HKI‐272 and Related Compounds for the Treatment of Cancer
Wissner, A., & Mansour, T. S. (2008) · Archiv der Pharmazie · doi:10.1002/ardp.200800009 · Cited by 174
Dual Role of Transforming Growth Factor β in Mammary Tumorigenesis and Metastatic Progression
Muraoka-Cook, R. S., Dumont, N., & Arteaga, C. L. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.937s.11.2 · Cited by 168
Scott Sawyer, J., Beight, D. W., Britt, K. S., Anderson, B. D., Campbell, R. M., Goodson, T., Herron, D. K., Li, H.-Y., McMillen, W. T., Mort, N., et al. (2004) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2004.04.007 · Cited by 166
Singh, J., Chuaqui, C. E., Boriack-Sjodin, P. A., Lee, W.-C., Pontz, T., Corbley, M. J., Cheung, H.-K., Arduini, R. M., Mead, J. N., Newman, M. N., et al. (2003) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2003.09.028 · Cited by 166
Anders, J., Kjær, S., & Ibáñez, C. F. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m104968200 · Cited by 163
Reversal of P-glycoprotein mediated multidrug resistance by novel anthranilamide derivatives
Roe, M., Folkes, A., Ashworth, P., Brumwell, J., Chima, L., Hunjan, S., Pretswell, I., Dangerfield, W., Ryder, H., & Charlton, P. (1999) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(99)00030-x · Cited by 163
Mauviel, A. (2005) · Humana Press eBooks · doi:10.1385/1-59259-940-0:069 · Cited by 159
Proteasome inhibitors as potential novel anticancer agents
Dou, Q. P., & Li, B. (1999) · Drug Resistance Updates · doi:10.1054/drup.1999.0095 · Cited by 158
Mai, A., Rotili, D., Tarantino, D., Ornaghi, P., Tosi, F., Vicidomini, C., Sbardella, G., Nebbioso, A., Miceli, M., Altucci, L., et al. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060601m · Cited by 155
Suzukake, K., Vistica, B. P., & Vistica, D. T. (1983) · Biochemical Pharmacology · doi:10.1016/0006-2952(83)90671-8 · Cited by 150
Kubo, K., Shimizu, T., Ohyama, S.-I., Murooka, H., Iwai, A., Nakamura, K., Hasegawa, K., Kobayashi, Y., Takahashi, N. K., Takahashi, K., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm030427r · Cited by 150
Vascular disrupting agents: a new class of drug in cancer therapy
Gaya, A. M., & Rustin, G. J. S. (2005) · Clinical Oncology · doi:10.1016/j.clon.2004.11.011 · Cited by 145
Chemical regulation of epigenetic modifications: Opportunities for new cancer therapy
Zheng, Y. G., Wu, J., Chen, Z., & Goodman, M. (2008) · Medicinal Research Reviews · doi:10.1002/med.20120 · Cited by 142
Fry, D. W. (1999) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(98)00050-3 · Cited by 140
Solomon, V. R., Hu, C., & Lee, H. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.01.001 · Cited by 135
Self-citationEscobedo, J. A., Barr, P. J., & Williams, L. T. (1988) · Molecular and Cellular Biology · doi:10.1128/mcb.8.12.5126 · Cited by 125
Developmental expression of the RET protooncogene.
Avantaggiato, V., Dathan, N. A., Grieco, M., Fabien, N., Lazzaro, D., Fusco, A., Simeone, A., & Santoro, M. (1994) · PubMed · Cited by 120
Histone acetyltransferase inhibitors and preclinical studies
Manzo, F., Tambaro, F. P., Mai, A., & Altucci, L. (2009) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543770902895727 · Cited by 119
Chen, Y., Zhao, Y., Lu, C., Tzeng, C., & Wang, J.-P. (2006) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2006.02.039 · Cited by 118
Hickey, K., Grehan, D., Reid, L. M., O’Briain, S., Walsh, T. N., & Hennessy, T. P. J. (1994) · Cancer · doi:10.1002/1097-0142(19940915)74:6<1693::aid-cncr2820740609>3.0.co;2-# · Cited by 117
Abouzid, K. A. M., & Shouman, S. A. (2008) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2008.07.038 · Cited by 114
Synthesis and Structure-Activity Relationships
勁一郎, 西., & Sasaki, M. (1998) · Journal of Pesticide Science · doi:10.1584/jpestics.23.429 · Cited by 109
Walker, J., Martin, C., & Callaghan, R. (2003) · European Journal of Cancer · doi:10.1016/j.ejca.2003.09.036 · Cited by 108
Tozer, G. M., Akerman, S., Cross, N. A., Barber, P. R., Björndahl, M. A., Greco, O., Harris, S., Hill, S. A., Honess, D. J., Ireson, C. R., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2011 · Cited by 106
Sinhababu, A. K., & Thakker, D. R. (1996) · Advanced Drug Delivery Reviews · doi:10.1016/0169-409x(95)00109-k · Cited by 105
Synthesis and Src Kinase Inhibitory Activity of a Series of 4-Phenylamino-3-quinolinecarbonitriles
Boschelli, D. H., Wang, Y. D., Ye, F., Wu, B., Zhang, N., Dutia, M. D., Powell, D. W., Wissner, A., Arndt, K. T., Weber, J. M., et al. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm000420z · Cited by 99
Src inhibitors: drugs for the treatment of osteoporosis, cancer or both?
Šušva, M., Missbach, M., & Green, J. (2000) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(00)01567-4 · Cited by 95
Interactions between Ras proteins and their effectors
McCormick, F. P., & Wittinghofer, A. (1996) · Current Opinion in Biotechnology · doi:10.1016/s0958-1669(96)80123-6 · Cited by 95
Martin, C., Berridge, G., Higgins, C. F., & Callaghan, R. (1997) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0701429 · Cited by 91
Identification of 4-hydroxyquinolines inhibitors of p300/CBP histone acetyltransferases
Mai, A., Rotili, D., Tarantino, D., Nebbioso, A., Castellano, S., Sbardella, G., Tini, M., & Altucci, L. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.12.097 · Cited by 88
Garton, A. J., Crew, A. P. A., Franklin, M. R., Cooke, A. R., Wynne, G. M., Castaldo, L., Kahler, J., Winski, S. L., Franks, A., Brown, E. N., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2873 · Cited by 85
5-Amino-2-Aroylquinolines as Highly Potent Tubulin Polymerization Inhibitors
Nien, C.-Y., Chen, Y.-C., Kuo, C., Hsieh, H., Chang, C.-Y., Wu, J., Wu, S., Liou, J., & Chang, J. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm900685y · Cited by 76
7-Alkoxy-4-phenylamino-3-quinolinecar-bonitriles as Dual Inhibitors of Src and Abl Kinases
Boschelli, D. H., Wang, Y. D., Johnson, S., Wu, B., Ye, F., Sosa, A. C. B., Golas, J. M., & Boschelli, F. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm0499458 · Cited by 72
Hu, C., Solomon, V. R., Ulíbarri, G., & Lee, H. (2008) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2008.07.076 · Cited by 67
Self-citationLi, H., McMillen, W. T., Heap, C. R., McCann, D., Yan, L., Campbell, R. M., Mundla, S. R., King, C.-H. R., Dierks, E. A., Anderson, B. D., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701199p · Cited by 67
Pawar, V. G., Sos, M. L., Rode, H. B., Rabiller, M., Heynck, S., van Otterlo, W. A. L., Thomas, R. K., & Rauh, D. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901877j · Cited by 65
Wissner, A., Floyd, M. B., Rabindran, S. K., Nilakantan, R., Greenberger, L. M., Shen, R., Wang, Y., & Tsou, H. (2002) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(02)00598-x · Cited by 65
Kim, Y., Shin, K.-J., Lee, T. G., Kim, E., Lee, M.-S., Ryu, S. H., & Suh, P. (2005) · Biochemical Pharmacology · doi:10.1016/j.bcp.2004.12.019 · Cited by 61
Reversal of multidrug resistance by a novel quinoline derivative, MS-209
Sato, W., Fukazawa, N., Nakanishi, O., Baba, M., Suzuki, T., Yano, O., Naito, M., & Tsuruo, T. (1995) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00689444 · Cited by 60
JONES, P. G., Altamura, S., Francesco, R. D., Paz, O. G., Kinzel, O. D., Mesiti, G., Monteagudo, E. S., Pescatore, G., Rowley, M., Verdirame, M., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800079s · Cited by 60
Kakadiya, R., Dong, H., Kumar, A., Dodia, N. M., Zhang, X., Chou, T., Lee, T., Shah, A. K., & Su, T. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.01.061 · Cited by 56
Moret, V., Laras, Y., Cresteil, T., Aubert, G., Ping, D. Q., Chen, D., Barthélémy-Requin, M., Béclin, C., Peyrot, V., Allegro, D., et al. (2008) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2008.03.042 · Cited by 54
Lunacridine from Lunasia amara is a DNA intercalating topoisomerase II inhibitor
Prescott, T. A. K., Sadler, I. H., Kiapranis, R., & Maciver, S. K. (2006) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2006.07.036 · Cited by 53
Kinzel, O. D., Llauger, L., Pescatore, G., Rowley, M., Schultz‐Fademrecht, C., Monteagudo, E. S., Fonsi, M., Paz, O. G., Fiore, F., Steinkühler, C., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm9004303 · Cited by 50
Circumvention of multidrug resistance by a newly synthesized quinoline derivative, MS-073.
Sato, W., Fukazawa, N., Suzuki, T., Yusa, K., & Tsuruo, T. (1991) · PubMed · Cited by 50
Zhang, N., Wu, B., Powell, D. W., Wissner, A., Floyd, M. B., Kovacs, E. D., Toral‐Barza, L., & Kohler, C. A. (2000) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(00)00580-1 · Cited by 49
Petti, F., Thelemann, A., Kahler, J., McCormack, S., Castaldo, L., Hunt, T., Nuwaysir, L. M., Zeiske, L., Haack, H., Sullivan, L. A., et al. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0114 · Cited by 45
Hu, C., Solomon, V. R., Cano, P., & Lee, H. (2009) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2009.11.017 · Cited by 32
Self-citationBoschelli, D. H., Wu, B., Ye, F., Wang, Y., Golas, J. M., Lucas, J., & Boschelli, F. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm061031t · Cited by 31
Discovering novel 3-nitroquinolines as a new class of anticancer agents
Li, H., Huang, H., Zhang, X., Luo, X., Lin, L., Jiang, H., Ding, J., Chen, K., & Liu, H. (2008) · Acta Pharmacologica Sinica · doi:10.1111/j.1745-7254.2008.00907.x · Cited by 27
The discovery of substituted 4-(3-hydroxyanilino)-quinolines as potent RET kinase inhibitors
Robinett, R. G., Freemerman, A. J., Skinner, M. A., Shewchuk, L. M., & Lackey, K. E. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.07.104 · Cited by 26
Zhang, N., Wu, B., Eudy, N. H., Wang, Y., Ye, F., Powell, D. W., Wissner, A., Feldberg, L. R., Kim, S. C., Mallon, R. G., et al. (2001) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(01)00238-4 · Cited by 26
Labrie, P., Maddaford, S. P., Lacroix, J., Catalano, C., Lee, D. K. H., Rakhit, S., & Gaudreault, R. C. (2006) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2006.07.055 · Cited by 25
Mucocutaneous cholinergic system is targeted in mustard-induced vesication
Grando, S. A. (2003) · Life Sciences · doi:10.1016/s0024-3205(03)00074-2 · Cited by 21
Sosa, A. C. B., Boschelli, D. H., Wu, B., Wang, Y., & Golas, J. M. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.01.004 · Cited by 19
4-Anilino-7-alkenylquinoline-3-carbonitriles as potent MEK1 kinase inhibitors
Berger, D. M., Dutia, M. D., Powell, D. W., Floyd, M. B., Torres, N., Mallon, R. G., Wojciechowicz, D. C., Kim, S., Feldberg, L. R., Collins, K. C., et al. (2008) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2008.09.009 · Cited by 16
Yagi, M., Kato, S., Kobayashi, Y., Kubo, K., Oyama, S., Shimizu, T., Nishitoba, T., Isoe, T., Nakamura, K., Ohashi, H., et al. (1997) · Experimental Cell Research · doi:10.1006/excr.1997.3616 · Cited by 16
Mallon, R. G., Feldberg, L. R., Kim, S., Collins, K. C., Wojciechowicz, D. C., Kohler, C. A., Kovacs, D., Discafani, C. M., Zhang, N., Wu, B., et al. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.755.3.6 · Cited by 16
Optimization of 7-alkene-3-quinolinecarbonitriles as Src kinase inhibitors
Boschelli, D. H., Wang, D. Y., Wang, Y., Wu, B., Honores, E. E., Sosa, A. C. B., Chaudhary, I., Golas, J. M., Lucas, J., & Boschelli, F. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.03.025 · Cited by 13
Jantová, S., Repický, A., Letašiová, S., & Čipák, L. (2008) · Cell Biochemistry and Function · doi:10.1002/cbf.1485 · Cited by 13
Cited by
Quinoline: A promising antitubercular target
Keri, R. S., & Patil, S. A. (2014) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2014.10.007 · Cited by 301
Metadata
- Authors
- R. Solomon, V., & Lee, H.
- Venue
- Current Medicinal Chemistry
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2011-04-01
- Volume
- 18
- Issue
- 10
- Pages
- 1488-1508
- ISSN
- 0929-8673 (ISSN-L)
- OpenAlex
- W2066404978
- Cited by
- 581
- References
- 112
- FWCI
- 10.77
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.